What's new

Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), Seladelpar lysine dihydrate, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), Seladelpar lysine dihydrate, Revision: 2, Status: Authorised

Apr 14, 2025 - 16:38
 0
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), Seladelpar lysine dihydrate, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), Seladelpar lysine dihydrate, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

Pharma bosses face down investor angst on tariffs, HHS chaos

Next Article

Another Headache For Fossil Fuels: Liquid Air Energy Storage

Related Posts

Summary of opinion: Prevymis, 27/02/2025 Positive

Summary of opinion: Prevymis, 27/02/2025 Positive

Feb 28, 2025  0

Human medicines European public assessment report (EPAR): Entecavir Viatris (previously Entecavir Mylan), entecavir, Date of authorisation: 18/09/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 10, 2025  0

Veterinary medicines safety day: Adverse event reportin...

Apr 8, 2025  0